- Home
- CRDL vs FCO Comparison
CRDL vs FCO Comparison
Compare CRDL & FCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- FCO
- Stock Information
- Founded
- CRDL 2017
- FCO 1991
- Country
- CRDL Canada
- FCO United Kingdom
- Employees
- CRDL N/A
- FCO N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- FCO Investment Managers
- Sector
- CRDL Health Care
- FCO Finance
- Exchange
- CRDL Nasdaq
- FCO Nasdaq
- Market Cap
- CRDL 105.8M
- FCO 85.6M
- IPO Year
- CRDL N/A
- FCO N/A
- Fundamental
- Price
- CRDL $1.37
- FCO $6.41
- Analyst Decision
- CRDL Strong Buy
- FCO
- Analyst Count
- CRDL 3
- FCO 0
- Target Price
- CRDL $9.33
- FCO N/A
- AVG Volume (30 Days)
- CRDL 231.5K
- FCO 100.1K
- Earning Date
- CRDL 08-11-2025
- FCO 01-01-0001
- Dividend Yield
- CRDL N/A
- FCO 14.96%
- EPS Growth
- CRDL N/A
- FCO N/A
- EPS
- CRDL N/A
- FCO 0.43
- Revenue
- CRDL N/A
- FCO N/A
- Revenue This Year
- CRDL N/A
- FCO N/A
- Revenue Next Year
- CRDL N/A
- FCO N/A
- P/E Ratio
- CRDL N/A
- FCO $12.30
- Revenue Growth
- CRDL N/A
- FCO N/A
- 52 Week Low
- CRDL $0.77
- FCO $4.73
- 52 Week High
- CRDL $2.63
- FCO $6.63
- Technical
- Relative Strength Index (RSI)
- CRDL 62.48
- FCO 60.54
- Support Level
- CRDL $1.22
- FCO $6.16
- Resistance Level
- CRDL $1.50
- FCO $6.41
- Average True Range (ATR)
- CRDL 0.09
- FCO 0.09
- MACD
- CRDL -0.01
- FCO -0.00
- Stochastic Oscillator
- CRDL 89.29
- FCO 82.14
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.